(Pfizer Pregnant COVID Vaccine C4591015) A PHASE 2/3, PLACEBO CONTROLLED, RANDOMIZED, OBSERVER BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS COV 2 RNA VACCINE CANDIDATE (BNT162b2) AGAINST COVID 19 IN HEALTHY PREGNANT WOME

Project: Other project

Project Details

StatusActive
Effective start/end date2/10/212/9/26

Funding

  • Pfizer, Inc.: $11,684.62